9vHPV vaccine + BCG vaccine

The **9vHPV vaccine + BCG vaccine** is an experimental combination therapy that merges the 9-valent human papillomavirus (HPV) vaccine (commercially known as Gardasil 9) with the Bacillus Calmette-Guérin (BCG) vaccine. The 9vHPV vaccine is designed to protect against nine HPV types, which are responsible for the majority of HPV-associated cancers and genital warts. The BCG vaccine, traditionally used for tuberculosis prevention, is known for its ability to enhance the immune system’s response via “trained immunity.” The rationale for this combination is that BCG may boost antigen presentation and immune activation, potentially improving the therapeutic response against persistent HPV infections or HPV-related disease. Early-phase clinical trials involve administering the two vaccines together percutaneously via a multiple puncture device, with the primary focus on safety, immune activation, and preliminary efficacy in treating HPV-related conditions[1][2][4].

Other names

9-valent human papillomavirus vaccine plus Bacillus Calmette–GuérinGardasil 9 plus BCG vaccineGardasil9 plus BCG vaccineGardasil-9 plus BCG vaccine9vHPV Vaccine plus BCG Vaccine Mix